A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Trial Profile

A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Bleselumab (Primary) ; Basiliximab; Meprednisone; Meprednisone; Mycophenolate mofetil; Mycophenolate mofetil; Prednisone; Tacrolimus; Tacrolimus
  • Indications Focal segmental glomerulosclerosis
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 30 Mar 2020 to 1 May 2020.
    • 28 Jun 2017 Planned primary completion date changed from 4 Sep 2019 to 1 Sep 2019.
    • 31 May 2017 Planned End Date changed from 1 Mar 2019 to 30 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top